



Financial Tear Sheet


Corporate Profile

Otonomy is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear. OTIPRIO (ciprofloxacin otic suspension) is approved in the United States for use during tympanostomy tube placement surgery in pediatric patients, and has achieved positive pivotal trial results in patients with acute otitis externa. OTO-104 is a steroid in development for the treatment of Ménière's disease and other severe balance and hearing disorders. Two Phase 3 trials in Ménière's disease patients are underway with results expected during the second half of 2017, and a Phase 2 trial has been initiated in patients at risk for cisplatin-induced hearing loss. OTO-311 is an NMDA receptor antagonist for the treatment of tinnitus that has completed a Phase 1 clinical safety trial with a Phase 2 trial expected to be initiated in the second half of 2017. Otonomy's proprietary formulation technology utilizes a thermosensitive gel and drug microparticles to enable single dose treatment by a physician.

Stock Performance

OTIC (Common Stock)

Exchange NASDAQ GS (US Dollar)
 Price **\$19.30**
 Change (%) ▼ **0.15 (0.77%)**
 Volume 133,057
 52 Week High \$20.15
 52 Week Low \$11.30
 Data as of 07/25/17 4:00 p.m. ET



Data Provided by Thomson Reuters

Recent Headlines & Events

- 07/18/17 - 7:30 a.m.
[Otonomy Announces FDA Acceptance of OTIPRIO® Supplemental New Drug Application Filing for Acute Otitis Externa](#)
- 06/22/17 - 7:30 a.m.
[Otonomy Announces Successful End-of-Phase 2 Review by FDA for OTIPRIO® in Acute Otitis Media with Tympanostomy Tubes](#)

There are currently no events scheduled.

SEC Filings

Filing Date	Form
07/14/17	4
07/14/17	4

Primary IR Contact

E-mail: ir@otonomy.com